Physician profile
Kevin Hazard
NPI 1881652089
$893.93
in general payments reported to CMS, 2019-2025
18 companies · $292 in 2025
The $292 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $110 · 2022: $26.53 · 2023: $169 · 2024: $296 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $340.11 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $153.16 | 2024-2025 | |
| Abbvie INC. | $81.91 | 2024-2025 | |
| Novo Nordisk INC | $43.12 | 2024 | |
| Xeris Pharmaceuticals, INC. | $40.41 | 2024-2025 | Recorlev |
| Sanofi-Aventis U.S. LLC | $34.58 | 2025 | |
| Medtronic, INC. | $29.99 | 2023 | Minimed 780g |
| Recor Medical INC | $23.29 | 2025 | Paradise Ultrasound Renal Denervation System |
| Dexcom, INC. | $21.06 | 2025 | Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $18.65 | 2025 | Yorvipath |
| Recordati_rare_diseases_inc. | $17.89 | 2025 | Isturisa |
| Echosens North America, INC. | $17.43 | 2025 | Fibroscan |
| Cequr Corporation | $16.05 | 2025 | Cequr Simplicity |
| Amphastar Pharmaceuticals, INC. | $15.53 | 2024 | |
| Amgen INC. | $15.36 | 2024 | Tepezza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Itamar Medical INC | $13.76 | 2025 | Watchpatone |
| Beta Bionics, INC. | $11.63 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Hazard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.